brain metastases brain metastases
Conditions
Interventions
two-session fractionated stereotactic radiotherapy
radiotherapy
Sponsors
Mizowaki Takashi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Age is 20 years or older (2) The primary tumor and metastases must be lung cancer or breast cancer (3) The patient must have at least one metastatic brain tumor with a maximum diameter of at least 15 mm and less than 30 mm (multiple brain metastases with a maximum diameter of less than 15 mm are acceptable) (4) Performance status (PS) 0, 1, or 2, or PS 3 due to tumor-related neurological symptoms only (5) No meningeal dissemination (6) No history of radiation therapy for intracranial lesions
Exclusion criteria
Exclusion criteria: Patients with psychosis or psychiatric symptoms that make it difficult for them to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of late adverse events at 6 months (CTCAE 5th edition grade 2 or higher) | — |
Secondary
| Measure | Time frame |
|---|---|
| Local control rate, rate of acute phase adverse events (CTCAE 5th edition grade 2 or higher), survival, intracranial distant recurrence rate, and rate of quality of life deterioration at the site of two-stage stereotactic radiotherapy at 6 months after treatment initiation | — |
Contacts
Public ContactTakashi Mizowaki
Department of Radiation Oncology and Image-applied Therapy, Kyoto University Graduate School of Medicine
Outcome results
None listed